NCT00862277

Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine

Evaluation of the Persistence of Bactericidal Antibodies in Adolescents and Adults Who Received a Single Dose of Menactra® Four to Eight Years Earlier

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 763 (actual)
• Sponsor: Sanofi Pasteur, a Sanofi Company · Industry
• Sex: All
• Age: 14 Years – 27 Years
• Healthy volunteers: Accepted

Summary

To evaluate the persistence of bactericidal antibodies in adolescents and adults who received one dose of Menactra® vaccine approximately four to eight years earlier

Detailed description

Subjects who received one dose of Menactra® or Menomune® in study MTA04, MTA12, MTA19 (NCT00777790), or MTA21 (NCT00777257) will be eligible for enrollment in trial this study. All eligible subjects will provide a blood sample at Visit 1, after which their participation in the study will be terminated. An age-matched meningococcal-vaccine naïve control group will be recruited to provide a blood sample for baseline antibody level evaluation. No vaccine will be administered in this study.

Conditions

• Meningococcal Infections
• Meningitis

Interventions

Type	Name	Description
BIOLOGICAL	Menactra®	0.5 mL, Intramuscular (from a previous study)
BIOLOGICAL	Menomune®	0.5 mL, Intramuscular (from a previous study)

Timeline

• Start date: 2008-12-01
• Primary completion: 2009-03-01
• Completion: 2009-12-01
• First posted: 2009-03-16
• Last updated: 2016-04-14
• Results posted: 2011-01-13

Locations

20 sites across 1 country: United States